Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Tabula Rasa price target raised to $45 from $41 at Piper Sandler » 14:49
05/07/21
05/07
14:49
05/07/21
14:49
TRHC

Tabula Rasa HealthCare

$47.06 /

+4.89 (+11.60%)

Piper Sandler analyst…

Piper Sandler analyst Sean Wieland raised the firm's price target on Tabula Rasa HealthCare to $45 from $41 and keeps a Neutral rating on the shares following the company's "solid" Q1 results. The analyst is encouraged by Tabula's investment in a seasoned sales force, and by the "early momentum these 40 reps have generated in the MedWise segment." However, Wieland remains on the sidelines due to execution risk.

ShowHide Related Items >><<
TRHC Tabula Rasa HealthCare
$47.06 /

+4.89 (+11.60%)

TRHC Tabula Rasa HealthCare
$47.06 /

+4.89 (+11.60%)

03/01/21
Fly Intel: Top five analyst downgrades
03/01/21 Truist
Tabula Rasa HealthCare downgraded to Hold from Buy at Truist
03/01/21 Truist
Tabula Rasa HealthCare downgraded to Hold from Buy at Truist
02/24/21 Piper Sandler
Tabula Rasa HealthCare downgraded to Neutral from Overweight at Piper Sandler
TRHC Tabula Rasa HealthCare
$47.06 /

+4.89 (+11.60%)

Thursday
Earnings
Tabula Rasa HealthCare sees FY21 revenue $336M-$356M, consensus $341.73M » 16:43
05/06/21
05/06
16:43
05/06/21
16:43
TRHC

Tabula Rasa HealthCare

$42.49 /

-4.12 (-8.84%)

Sees FY21 adjusted EBITDA…

Sees FY21 adjusted EBITDA $26M-$32M.

ShowHide Related Items >><<
TRHC Tabula Rasa HealthCare
$42.49 /

-4.12 (-8.84%)

TRHC Tabula Rasa HealthCare
$42.49 /

-4.12 (-8.84%)

03/01/21
Fly Intel: Top five analyst downgrades
03/01/21 Truist
Tabula Rasa HealthCare downgraded to Hold from Buy at Truist
03/01/21 Truist
Tabula Rasa HealthCare downgraded to Hold from Buy at Truist
02/24/21 Piper Sandler
Tabula Rasa HealthCare downgraded to Neutral from Overweight at Piper Sandler
TRHC Tabula Rasa HealthCare
$42.49 /

-4.12 (-8.84%)

Earnings
Tabula Rasa HealthCare sees Q2 revenue $80.5M-$82.5M, consensus $81.62M » 16:42
05/06/21
05/06
16:42
05/06/21
16:42
TRHC

Tabula Rasa HealthCare

$42.49 /

-4.12 (-8.84%)

Sees Q2 adjusted EBITDA…

Sees Q2 adjusted EBITDA $5.5M-$6.5M.

ShowHide Related Items >><<
TRHC Tabula Rasa HealthCare
$42.49 /

-4.12 (-8.84%)

TRHC Tabula Rasa HealthCare
$42.49 /

-4.12 (-8.84%)

03/01/21
Fly Intel: Top five analyst downgrades
03/01/21 Truist
Tabula Rasa HealthCare downgraded to Hold from Buy at Truist
03/01/21 Truist
Tabula Rasa HealthCare downgraded to Hold from Buy at Truist
02/24/21 Piper Sandler
Tabula Rasa HealthCare downgraded to Neutral from Overweight at Piper Sandler
TRHC Tabula Rasa HealthCare
$42.49 /

-4.12 (-8.84%)

Earnings
Tabula Rasa HealthCare reports Q1 adjusted EPS (9c), consensus (9c) » 16:41
05/06/21
05/06
16:41
05/06/21
16:41
TRHC

Tabula Rasa HealthCare

$42.49 /

-4.12 (-8.84%)

Reports Q1 revenue…

Reports Q1 revenue $76.7M, consensus $76.15M.

ShowHide Related Items >><<
TRHC Tabula Rasa HealthCare
$42.49 /

-4.12 (-8.84%)

TRHC Tabula Rasa HealthCare
$42.49 /

-4.12 (-8.84%)

03/01/21
Fly Intel: Top five analyst downgrades
03/01/21 Truist
Tabula Rasa HealthCare downgraded to Hold from Buy at Truist
03/01/21 Truist
Tabula Rasa HealthCare downgraded to Hold from Buy at Truist
02/24/21 Piper Sandler
Tabula Rasa HealthCare downgraded to Neutral from Overweight at Piper Sandler
TRHC Tabula Rasa HealthCare
$42.49 /

-4.12 (-8.84%)

Over a week ago
Hot Stocks
Tabula Rasa HealthCare expands COVID-19 services for pharmacies » 08:16
04/13/21
04/13
08:16
04/13/21
08:16
TRHC

Tabula Rasa HealthCare

$43.86 /

+0.77 (+1.79%)

Tabula Rasa HealthCare…

Tabula Rasa HealthCare announced an expansion of COVID-19 services for independent and chain pharmacies. TRHC's technology-driven patient engagement solutions will support pharmacists in the administration of and reporting for the COVID-19 vaccine. Through TRHC's PrescribeWellness patient-relationship management solution, community pharmacies can achieve expanded patient reach during the critical, nationwide rollout of the COVID-19 vaccine. Innovative services such as contact-free vaccination management - a virtual, patient-friendly vaccination intake and scheduling tool - enable community pharmacies to engage their patients effectively and safely for the administration of the COVID-19 vaccine and beyond.

ShowHide Related Items >><<
TRHC Tabula Rasa HealthCare
$43.86 /

+0.77 (+1.79%)

TRHC Tabula Rasa HealthCare
$43.86 /

+0.77 (+1.79%)

03/01/21
Fly Intel: Top five analyst downgrades
03/01/21 Truist
Tabula Rasa HealthCare downgraded to Hold from Buy at Truist
03/01/21 Truist
Tabula Rasa HealthCare downgraded to Hold from Buy at Truist
02/24/21 Piper Sandler
Tabula Rasa HealthCare downgraded to Neutral from Overweight at Piper Sandler
TRHC Tabula Rasa HealthCare
$43.86 /

+0.77 (+1.79%)

TRHC Tabula Rasa HealthCare
$43.86 /

+0.77 (+1.79%)

Over a month ago
Downgrade
Fly Intel: Top five analyst downgrades » 09:53
03/01/21
03/01
09:53
03/01/21
09:53
FTI

TechnipFMC

$8.36 /

+0.135 (+1.64%)

, RMAX

RE/MAX Holdings

$42.02 /

+0.01 (+0.02%)

, TRHC

Tabula Rasa HealthCare

$39.95 /

-0.56 (-1.38%)

, BGNE

BeiGene

$321.45 /

+1.68 (+0.53%)

, ZIOP

Ziopharm

$5.10 /

-0.23 (-4.32%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. TechnipFMC (FTI) downgraded to Equal Weight at Morgan Stanley with analyst Sasikanth Chilukuru saying if the current market cap of Technip Energies (THNPF) is used, rather than the firm's own fair value estimate, than there is no upside seen for TechnipFMC shares. 2. RE/MAX Holdings downgraded to Neutral from Buy at Compass Point with analyst Matthew Gaudioso saying after appreciating 34% since the company's Q3 earnings call, the stock is now trading slightly above its recent historical multiples. 3. Tabula Rasa HealthCare (TRHC) downgraded to Hold from Buy at Truist with analyst Sandy Draper saying the firm's Buy rating was predicated on steady high teens to 20% growth in CareVention and accelerating growth and margin expansion in the MedWise business, and while CareVention has been "OK," COVID is pressuring census and keeping growth muted. 4. BeiGene (BGNE) downgraded to Underperform from Outperform at CLSA with analyst Tony Ren citing a weaker sales forecast, a higher forecast for R&D spending due to the collaboration with Novartis (NVS), sentiment, and what he sees as a lack of meaningful clinical, regulatory or revenue catalysts for his cut to his rating for BeiGene. 5. Ziopharm (ZIOP) downgraded to Neutral from Buy at H.C. Wainwright with analyst Swayampakula Ramakanth seeing questions on the company's direction following the CEO change. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
ZIOP Ziopharm
$5.10 /

-0.23 (-4.32%)

TRHC Tabula Rasa HealthCare
$39.95 /

-0.56 (-1.38%)

RMAX RE/MAX Holdings
$42.02 /

+0.01 (+0.02%)

FTI TechnipFMC
$8.36 /

+0.135 (+1.64%)

BGNE BeiGene
$321.45 /

+1.68 (+0.53%)

FTI TechnipFMC
$8.36 /

+0.135 (+1.64%)

03/01/21 Morgan Stanley
TechnipFMC downgraded to Equal Weight at Morgan Stanley
03/01/21 Morgan Stanley
TechnipFMC downgraded to Equal Weight from Overweight at Morgan Stanley
02/22/21 Barclays
TechnipFMC downgraded to Equal Weight from Overweight at Barclays
02/18/21
Fly Intel: Top five analyst downgrades
RMAX RE/MAX Holdings
$42.02 /

+0.01 (+0.02%)

03/01/21 Compass Point
RE/MAX Holdings downgraded to Neutral on valuation at Compass Point
12/21/20 JPMorgan
JPMorgan changes ratings in REIT, Real Estate Services sectors into 2021
12/21/20 JPMorgan
RE/MAX Holdings upgraded to Neutral from Underweight at JPMorgan
06/18/20 Zelman
Armstrong World added to Top Idea Basket as a Sell at Zelman
TRHC Tabula Rasa HealthCare
$39.95 /

-0.56 (-1.38%)

03/01/21 Truist
Tabula Rasa HealthCare downgraded to Hold from Buy at Truist
03/01/21 Truist
Tabula Rasa HealthCare downgraded to Hold from Buy at Truist
02/24/21 Piper Sandler
Tabula Rasa HealthCare downgraded to Neutral from Overweight at Piper Sandler
02/24/21 Cantor Fitzgerald
Cantor downgrades Tabula Rasa HealthCare to Neutral on 'underwhelming' outlook
BGNE BeiGene
$321.45 /

+1.68 (+0.53%)

03/01/21 CLSA
BeiGene downgraded to Underperform from Outperform at CLSA
02/18/21 Cowen
BeiGene price target raised to $429 from $348 at Cowen
01/12/21 Piper Sandler
BeiGene price target raised to $190 from $185 at Piper Sandler
12/29/20 Piper Sandler
BeiGene NRDL inclusions 'absolutely critical,' says Piper Sandler
ZIOP Ziopharm
$5.10 /

-0.23 (-4.32%)

03/01/21 H.C. Wainwright
Ziopharm downgraded to Neutral from Buy at H.C. Wainwright
07/10/20 Lake Street
Ziopharm took 'important step' with start of CAR-T study, says Lake Street
06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
ZIOP Ziopharm
$5.10 /

-0.23 (-4.32%)

TRHC Tabula Rasa HealthCare
$39.95 /

-0.56 (-1.38%)

RMAX RE/MAX Holdings
$42.02 /

+0.01 (+0.02%)

FTI TechnipFMC
$8.36 /

+0.135 (+1.64%)

BGNE BeiGene
$321.45 /

+1.68 (+0.53%)

  • 02
    Dec
FTI TechnipFMC
$8.36 /

+0.135 (+1.64%)

ZIOP Ziopharm
$5.10 /

-0.23 (-4.32%)

TRHC Tabula Rasa HealthCare
$39.95 /

-0.56 (-1.38%)

FTI TechnipFMC
$8.36 /

+0.135 (+1.64%)

FTI TechnipFMC
$8.36 /

+0.135 (+1.64%)

Downgrade
Tabula Rasa HealthCare downgraded to Hold from Buy at Truist » 07:28
03/01/21
03/01
07:28
03/01/21
07:28
TRHC

Tabula Rasa HealthCare

$40.57 /

-0.57 (-1.39%)

Truist analyst Sandy…

Truist analyst Sandy Draper downgraded Tabula Rasa HealthCare to Hold from Buy with a price target of $42, up from $41. The firm's Buy rating was predicated on steady high teens to 20% growth in CareVention and accelerating growth and margin expansion in the MedWise business, and while CareVention has been "OK," COVID is pressuring census and keeping growth muted, Draper tells investors in a research note. The analyst expects 2022 to improve, but sees more risks than catalysts in 2021.

ShowHide Related Items >><<
TRHC Tabula Rasa HealthCare
$40.57 /

-0.57 (-1.39%)

TRHC Tabula Rasa HealthCare
$40.57 /

-0.57 (-1.39%)

03/01/21 Truist
Tabula Rasa HealthCare downgraded to Hold from Buy at Truist
02/24/21 Piper Sandler
Tabula Rasa HealthCare downgraded to Neutral from Overweight at Piper Sandler
02/24/21 Cantor Fitzgerald
Cantor downgrades Tabula Rasa HealthCare to Neutral on 'underwhelming' outlook
02/24/21 Cantor Fitzgerald
Tabula Rasa HealthCare downgraded to Neutral at Cantor Fitzgerald
TRHC Tabula Rasa HealthCare
$40.57 /

-0.57 (-1.39%)

TRHC Tabula Rasa HealthCare
$40.57 /

-0.57 (-1.39%)

Downgrade
Tabula Rasa HealthCare downgraded to Hold from Buy at Truist » 06:17
03/01/21
03/01
06:17
03/01/21
06:17
TRHC

Tabula Rasa HealthCare

$40.57 /

-0.57 (-1.39%)

Truist analyst Sandy…

Truist analyst Sandy Draper downgraded Tabula Rasa HealthCare to Hold from Buy with a $42 price target.

ShowHide Related Items >><<
TRHC Tabula Rasa HealthCare
$40.57 /

-0.57 (-1.39%)

TRHC Tabula Rasa HealthCare
$40.57 /

-0.57 (-1.39%)

02/24/21 Piper Sandler
Tabula Rasa HealthCare downgraded to Neutral from Overweight at Piper Sandler
02/24/21 Cantor Fitzgerald
Cantor downgrades Tabula Rasa HealthCare to Neutral on 'underwhelming' outlook
02/24/21 Cantor Fitzgerald
Tabula Rasa HealthCare downgraded to Neutral at Cantor Fitzgerald
02/02/21 RBC Capital
Tabula Rasa HealthCare price target raised to $70 from $54 at RBC Capital
TRHC Tabula Rasa HealthCare
$40.57 /

-0.57 (-1.39%)

TRHC Tabula Rasa HealthCare
$40.57 /

-0.57 (-1.39%)

Downgrade
Tabula Rasa HealthCare downgraded to Neutral from Overweight at Piper Sandler » 17:04
02/24/21
02/24
17:04
02/24/21
17:04
TRHC

Tabula Rasa HealthCare

$45.51 /

-2.17 (-4.55%)

Piper Sandler analyst…

Piper Sandler analyst Sean Wieland downgraded Tabula Rasa HealthCare to Neutral from Overweight with a price target of $41, up from $40. Wieland said he lacks conviction in the company's "ability to execute" on what he sees as an "aggressive, and back-half weighted, FY21 guide." The analyst added that he sees headwinds to revenue and adjusted EBITDA targets, and "can't continue to give the company credit for bookings and pipeline successes when conversions seem to be perpetually delayed." Wieland downgrades the stock to Neutral "pending evidence of execution."

ShowHide Related Items >><<
TRHC Tabula Rasa HealthCare
$45.51 /

-2.17 (-4.55%)

TRHC Tabula Rasa HealthCare
$45.51 /

-2.17 (-4.55%)

02/24/21 Cantor Fitzgerald
Cantor downgrades Tabula Rasa HealthCare to Neutral on 'underwhelming' outlook
02/24/21 Cantor Fitzgerald
Tabula Rasa HealthCare downgraded to Neutral at Cantor Fitzgerald
02/02/21 RBC Capital
Tabula Rasa HealthCare price target raised to $70 from $54 at RBC Capital
01/22/21 Baird
Tabula Rasa HealthCare may have lost MTM deal at Aetna, says Baird
TRHC Tabula Rasa HealthCare
$45.51 /

-2.17 (-4.55%)

TRHC Tabula Rasa HealthCare
$45.51 /

-2.17 (-4.55%)

Downgrade
Cantor downgrades Tabula Rasa HealthCare to Neutral on 'underwhelming' outlook » 11:23
02/24/21
02/24
11:23
02/24/21
11:23
TRHC

Tabula Rasa HealthCare

$48.68 /

+1 (+2.10%)

As previously reported,…

As previously reported, Cantor Fitzgerald analyst Steven Halper downgraded Tabula Rasa HealthCare to Neutral from Overweight with an unchanged price target of $40 after the company reported what he called "solid" Q4 results but gave 2021 guidance he called "underwhelming." The company's 2021 revenue guidance implying about 16% year-over-year growth "seems reasonable," but its adjusted EBITDA guidance was "disappointing," said Halper, who has reduced his own adjusted EBITDA estimate following the outlook commentary from the company. He thinks it will be "at least a few quarters" until there is better visibility into 2022, the analyst added.

ShowHide Related Items >><<
TRHC Tabula Rasa HealthCare
$48.68 /

+1 (+2.10%)

TRHC Tabula Rasa HealthCare
$48.68 /

+1 (+2.10%)

02/24/21 Cantor Fitzgerald
Tabula Rasa HealthCare downgraded to Neutral at Cantor Fitzgerald
02/02/21 RBC Capital
Tabula Rasa HealthCare price target raised to $70 from $54 at RBC Capital
01/22/21 Baird
Tabula Rasa HealthCare may have lost MTM deal at Aetna, says Baird
01/15/21 Stifel
Tabula Rasa HealthCare downgraded to Hold from Buy at Stifel
TRHC Tabula Rasa HealthCare
$48.68 /

+1 (+2.10%)

TRHC Tabula Rasa HealthCare
$48.68 /

+1 (+2.10%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.